Best Single Test: Antinuclear Antibodies (ANA)
For a young woman presenting with fatigue, myalgia, arthralgia, alopecia, weight loss, and erythematous facial plaques—a constellation highly suggestive of systemic lupus erythematosus (SLE)—the single best initial test is ANA by indirect immunofluorescence on HEp-2 cells at a titer ≥1:80.
Rationale for ANA as the Entry Test
The clinical presentation described is classic for SLE: constitutional symptoms (fatigue, weight loss), musculoskeletal involvement (myalgia, arthralgia), dermatologic manifestations (erythematous facial plaques consistent with malar or discoid rash), and alopecia. This multi-system involvement in a young woman makes SLE the primary diagnostic consideration.
ANA serves as the mandatory entry criterion for SLE classification according to the EULAR/ACR 2019 criteria 1. This represents a strategic shift from previous classification systems where ANA had equal weight with other autoantibodies. The test must show a titer ≥1:80 by indirect immunofluorescence on HEp-2 cells to be considered positive 1.
Why ANA First?
- High sensitivity: ANA at ≥1:80 maintains 95.8% sensitivity for SLE 1
- Screening function: A negative ANA at this cutoff essentially rules out SLE in most cases
- Gateway test: Positive ANA then directs the next phase of testing (anti-dsDNA, anti-Sm, complement levels, complete blood count, urinalysis) 2
Important Caveats About ANA Testing
Specificity Limitations
ANA at 1:80 has only 74.7% specificity for SLE 1. This means:
- Positive results occur in other rheumatologic diseases
- Healthy individuals can test positive
- The low positive likelihood ratio means clinical manifestations remain paramount for diagnosis
If you want better diagnostic performance, consider that specificity increases to 86.2% at a 1:160 dilution while maintaining 95.8% sensitivity 1. However, the 1:80 cutoff remains the standard entry criterion.
Clinical Context is Critical
The relatively low specificity at 1:80 is precisely why this cutoff works well as a classification criterion—it captures a heterogeneous group that requires further subclassification 1. In clinical practice with low pre-test probability, positive ANA results must trigger additional specific testing rather than confirming diagnosis alone 1.
The Diagnostic Algorithm After ANA
Once ANA is positive, the baseline autoantibody panel should include 2:
- Anti-dsDNA (correlates with disease activity and renal involvement)
- Anti-Ro, anti-La (prognostic value, neonatal lupus risk)
- Anti-RNP, anti-Sm (diagnostic specificity)
- Anti-phospholipid antibodies (thrombotic risk, pregnancy complications)
- Complement C3, C4 (disease activity marker)
Additional essential baseline tests include complete blood count (assess for cytopenias), comprehensive metabolic panel (renal function), and urinalysis with protein/creatinine ratio (renal involvement) 2.
Why Not Other Tests First?
- Anti-dsDNA alone: More specific but less sensitive; would miss ANA-negative or anti-dsDNA-negative SLE cases
- Skin biopsy: Useful for confirming cutaneous lupus but doesn't assess systemic involvement 2
- Complete blood count: May show cytopenias but lacks diagnostic specificity for SLE
- ESR/CRP: CRP is often normal in active SLE; elevated CRP should raise suspicion for superimposed infection 2
Practical Implementation
Request ANA with the following specifications:
- Method: Indirect immunofluorescence on HEp-2 cells
- Report titer and pattern
- Include comprehensive clinical information with the request so the laboratory can recommend appropriate reflex testing 1
If ANA is positive at ≥1:80, immediately order the complete autoantibody panel and baseline organ function assessment listed above. This approach maximizes diagnostic efficiency while maintaining sensitivity for this potentially life-threatening disease that requires early recognition and treatment to prevent organ damage and improve long-term outcomes.